Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer | NEJM
PRIMA study design. CR complete response, PR partial response, PFS... | Download Scientific Diagram
Niraparib Prolongs PFS in Patients with Newly Diagnosed Advanced
Efficacy | ZEJULA (niraparib) for HCPs
Efficacy | ZEJULA (niraparib) for HCPs
Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer - ScienceDirect
Niraparib Efficacy and Safety in Patients with BRCA-Mutated (BRCAm) Ovarian Cancer: Results from Three Phase 3 Niraparib Trials
Niraparib in the PRIMA Trial
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer | NEJM
Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer - European Journal of
OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab - ScienceDirect
Efficacy | ZEJULA (niraparib) for HCPs
Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME Study): A randomized, double-blind, placebo-controlled, phase 3 trial (LBA 5) -
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer | NEJM
Safety and management of niraparib monotherapy in ovarian cancer clinical trials | International Journal of Gynecologic Cancer
Inhibidores de PARP en primera línea de cáncer de ovario | PPT
Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count : results from the PRIMA/ENGOT-OV26/GOG-3012 trial
PARP Inhibitors. - ppt download
PARP inhibitor in Ca Ovary | PPT
Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer | Targeted Oncology
Efficacy of niraparib in the PRIMA phase III trial | Download Scientific Diagram
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer | NEJM
Stephen V Liu, MD on X: "#ESMO19 Practice changing study presented by Antonio Gonzalez Martin. PRIMA study of niraparib in patients with ovarian cancer responding to 1L platinum based chemo. Primary endpoint
Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial - Maria-Pilar Barretina-Ginesta, Bradley J. Monk, Sileny Han, Bhavana
Efficacy of niraparib in the PRIMA trial | Download Scientific Diagram
